medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2011, Number S2

<< Back Next >>

Ann Hepatol 2011; 10 (S2)

Efficacy of oral L-ornithine L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy

Blanco VCI, Poo RJL

Language: English
References: 29
Page: 55-59
PDF size: 1335.23 Kb.


ABSTRACT

Hyperammonemia and associated cerebral edema cause neurological abnormalities in liver disease patients. Although only 15% of ammonia production originates in the colon, management strategies for hepatic encephalopathy (HE) have focused on reducing ammonia generation from the bowel rather than on manipulating systemic mechanisms involved in ammonia metabolism. Administration of L-ornithine L-aspartate (LOLA) improves mental status and decreases serum and spinal fluid ammonia levels by stimulating both the urea cycle and glutamine (Gln) synthesis, which are key metabolic pathways in ammonia detoxification. LOLA was shown to be superior to a placebo for management of HE, and the results of several clinical trials suggest that its effectiveness could be higher with the more severe grades of this syndrome. Compared with the standard treatment, LOLA is effective not only in reducing hyperammonemia and the severity of this disease, but also in improving the patient’s perceived quality of life. Therefore, LOLA is a promising alternative for the management of HE


REFERENCES

  1. Das A, Dhiman RK, Saraswat VA, Verma M, Naik SR. Prevalence and natural history of subclinical hepatic encephalopathy in cirrhosis. J Gastroenterol Hepatol 2001; 16: 531-5.

  2. Bustamante J, Rimola A, Ventura PJ, et al. Prognostic significance of hepatic encephalopathy in patients with cirrhosis. J Hepatol 1999; 30: 890-5.

  3. Poordad FF. The burden of hepatic encephalopathy. Aliment Pharmacol Ther 2007; 25(1): 3-9.

  4. Als-Nielsen B, Gluud LL, Gluud C. Nonabsorbable disaccharides for hepatic encephalopathy: systematic review of randomized trials. BMJ 2004; 328(7447): 1046.

  5. James LA, Lunn PG, Middleton S, Elia M. Distribution of glutaminase and glutamine synthetase activities in the human gastrointestinal tract. Clin Sci 1998; 94(3): 313-9.

  6. Romero-Gómez M, Jover M, Galán JJ, Ruiz A. Gut ammonia production and its modulation. Metab Brain Dis 2009; 24(1): 147-57.

  7. Olde DSW, Jalan R, Redhead DN, Hayes PC, Deutz NE, Soeters PB. Interorgan ammonia and amino acid metabolism in metabolically stable patients with cirrhosis and a TIPSS. Hepatology 2002; 36(5): 1163-71.

  8. Haüssinger D. Nitrogen metabolism in liver: structural and functional organization and physiological relevance. Biochem J 1990; 267(2): 281-90.

  9. Stahl J. Studies of the blood ammonia in liver disease. Its diagnostic, prognostic, and therapeutic significance. Ann Intern Med 1963; 58: 1-24.

  10. Dejong CH, Deutz NE, Soeters PB. Renal ammonia and glutamine metabolism during liver insufficiency-induced hyperammonemia in the rat. J Clin Invest 1993; 92(6): 2834-40.

  11. Lockwood AH, McDonald JM, Reiman RE, Gelbard AS, Laughlin JS, Duffy TE, Plum F. The dynamics of ammonia metabolism in man. Effects of liver disease and hyperammonemia. J Clin Invest 1979; 63(3): 449-60.

  12. Hazell A, Butterworth R. Hepatic encephalopathy: an update of pathophysiologic mechanisms. Exp Biol Med 1999; 222: 99-112.

  13. Norenberg MD, Rao KV, Jayakumar AR. Mechanisms of ammonia- induced astrocyte swelling. Metab Brain Dis 2005; 20(4): 303-18.

  14. Ranjan P, Mishra A, Kale R, Saraswat V, Gupta R. Cytotoxic edema is responsible for raised intracranial pressure in fulminant hepatic failure: in vivo demonstration using diffusion-weighted MRI in human subjects. Metab Brain Dis 2005; 20(3): 181-92.

  15. Gibson JB. Encephalopathy after portacaval shunt. Br Med J 1963; 1: 1652-55.

  16. Morgan KZ, Binks W, Brues AM, Cipriani AJ, Langham WH, Marinelli LD, et al. Report of International Subcommittee II on permissible dose for internal radiation. Br J Radiol Suppl 1955; 6: 25.

  17. Jalan R, Kapoor D. Enhanced renal ammonia excretion following volume expansion in patients with well compensated cirrhosis of the liver. Gut 2003; 52(7): 1041-5.

  18. Leonhardt H, Bungert HJ. Therapie der schweren Hyperammoniämie. Med Klin 1972; 67: 1052-6.

  19. Kircheis G, Nilius R, Held C, Berndt H, Buchner M, Görtelmeyer R, et al. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, doubleblind study. Hepatology 1997; 25(6): 1351-60.

  20. Rose C, Michalak A, Rao KV, Quack G, Kircheis G, Butterworth RF. L-ornithine-L-aspartate lowers plasma and spinal fluid ammonia and prevents brain edema in rats with acute liver failure. Hepatology 1999; 30(3): 636-40.

  21. Gebhardt R, Beckers G, Gaunitz F, Haupt W, Jonitza D, Klein S, et al. Treatment of cirrhotic rats with L-ornithine- L-aspartate enhances urea synthesis and lowers serum ammonia levels. J Pharmacol Exp Ther 1997; 283(1): 1-6.

  22. Rose C, Michalak A, Pannunzio P, Therrien G, Quack G, Kircheis G, Butterworth RF. L-ornithine-L-aspartate in experimental portal-systemic encephalopathy: therapeutic efficacy and mechanism of action. Metab Brain Dis 1998; 13(2): 147-57.

  23. Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT. Hepatic encephalopathy-definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002; 35(3): 716-21.

  24. Poo JL, Góngora J, Sánchez-Avila F, Aguilar-Castillo S, García- Ramos G, Fernández-Zertuche M, et al. Efficacy of oral L-ornithine-L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy. Results of a randomized, lactulose-controlled study. Ann Hepatol 2006; 5(4): 281-8.

  25. Stauch S, Kircheis G, Adler G, Beckh K, Ditschuneit H, Görtelmeyer R, et al. Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo- controlled double-blind study. J Hepatol 1998; 28(5): 856-64.

  26. Kircheis G, Wettstein M, Von Dahl S, Häussinger D. Clinical efficacy of L-ornithine–L-aspartate in the management of hepatic encephalopathy. Metab Brain Dis 2002; 17(4): 453-62.

  27. Kircheis G, Metz M, Frey S, Seiller E. Correlation between pharmacokinetic aspects and clinical efficacy of L-ornithine– L-aspartate (OA): results of randomized, controlled clinical trials. J Hepatol 1996; 25(Suppl. 1): 131 (abstract).

  28. Kersh E, Rifkin H. Lactulose enemas. Ann Intern Med 1973; 78(1): 81-4.

  29. Jiang Q, Jiang XH, Zheng MH, Chen YP. L-Ornithine-L-aspartate in the management of hepatic encephalopathy: a meta-analysis. J Gastroenterol Hepatol 2008; 24(1): 9-14.




2020     |     www.medigraphic.com